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Abstract
Background: Malignant gliomas are the most common in central nervous system cancer. Genome-wide
association study identifies that CDKN2A was a susceptibility loci for glioma. The CDKN2A/cyclin-dependent kinase
4, 6/Retinoblastoma protein (Rb) pathway is thought to play a crucial role in malignant gliomas pathogenesis. We
have investigated the expression of CDKN2A for potential correlations with malignant gliomas grade and potential
role of CDKN2A on malignant gliomas pathogenesis.
Methods: Tumour tissue samples from 61 patients suffering from malignant gliomas were investigated. The
expression levels of CDKN2A were detected using immunohistochemical staining and western blot. Overexpression
and knockdown of CDKN2A were performed in human glioma cell lines. Subsequently, colony formation, growth
curves and CDKN2A-Cyclin-Rb pathway were analyzed.
Results: Here we show that a lower expression of CDKN2A and a higher expression of cyclin D1 in the patients
with high-grade malignant gliomas than low-grade gliomas, respectively. Moreover, overexpression of CDKN2A
inhibits growth of glioma cell lines by suppression of cyclin D1 gene expression.
Conclusions: Our study suggests that CDKN2A as a malignant gliomas suppressor gene, appears to be useful for
predicting behaviour of high-grade malignant gliomas. CDKN2A-Cyclin-Rb pathway plays a key role on malignant
gliomas formation and that therapeutic targeting of this pathway may be useful in malignant gliomas treatment.
Background
Glioma is the most frequent primary intracranial
tumour in both adults and children. Their incidence
rate is about 6.42 cases/100,000 [1]. The molecular
genetic alterations with the development and pathogen-
esis of human gliomas have been widely studied [2].
Germline mutations, somatic mutation, disruption, copy
number variation of genes and loci contribute to the
pathogenesis of glioma [3-7]. Genetic alterations fre-
quently involved, include amplification of genes encod-
ing for receptor tyrosine kinases (EGFR, PDGFRA),
onocogens (PDGF, PDGFR, CDK4) and deletions/muta-
tions in tumor suppressor genes (IDH1, IDH2, TP53,
CDKN2A, PTEN)[6,8]. In recent years, the molecular
understanding of glioma has greatly increased. Activa-
tion of the MAPK/ERK and PI3K/AKT pathways are
hallmarks of a variety of malignancies, including mela-
noma and high-grade astrocytomas [6]. CDKN2A, a
tumor suppressor protein, has been shown to block
MDM2-induced degradation of p53 and enhancing p53-
dependent transactivation and apoptosis. CDKN2A also
binds to CDK4 and CDK6 and suppresses proliferation
by inhibiting cells progressing from G1 into S phase [9].
We reported that expression of CDKN2A (encoding
p16 protien) was lower in the patients with high-grade
malignant glioma than low-grade glioma. Moreover,
overexpression of CDKN2A inhibits growth of glioma
cell lines by suppression of cyclin D1 gene expression.
Methods
Tissue samples and cell lines
A total of 61 patients with malignant glioma were
included in this study. All patients underwent surgery at
Xiangya Secondary Hospital during the period 2009-
2010 in accordance with China law and ethical guide-
lines, and informed consent was obtained from patients
prior to resection. Glioma cells (T98G, U251-MG, U87-
MG, A172, SW1736, U118-MG, U138-MG, H4 and HS-
683) were purchased from ATCC and were cultured in
* Correspondence: wang_bing2011@yahoo.com.cn
Department of Spinal Surgery, Second Xiangya Hospital, Central South
University, 139 RenMin Road, Changsha, China
Liu et al. Journal of Experimental & Clinical Cancer Research 2011, 30:76
http://www.jeccr.com/content/30/1/76
© 2011 Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Dulbecco’s modified Eagle’s medium (GIBCO) supple-
mented with 10% fetal bovine serum (GIBCO) and 4
mM glutamine.
Immunohistochemistry
Paraffin-embedded sections were deparaffinized and
subjected to immunohistochemical staining for
CDKN2A with CDKN2A monoclonal antibody (Cell Sig-
nal Technology). The sections were microwaved in 10
mM sodium citrate buffer (pH 6.0) at 10 min intervals
f o rat o t a lo f2 0m i n .E n d o g e n ous peroxidase activity
was blocked by incubating the sections in a solution of
3.0% hydrogen peroxide for 20 min at room tempera-
ture. After washing in PBS the sections were incubated
with the primary CDKN2A monoclonal antibody
(1:100), overnight at 4°C. The sections were washed
with PBS and incubated with biotinylated secondary
antibody for 30 minutes, followed by incubation with
streptavidin-biotin-peroxidase complex a solution 3-
3’diaminobenzidine (Sigma), containing 1.0% hydrogen
peroxide and lightly counterstained with Harris
hematoxylin.
Western blot
Tissues form patients were homogenized with lysis
buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1%
sodium deoxycholate, 0.1% SDS, 20 mM EDTA, 1 mM
NaF, and 1% Triton X-100 (pH 7.4) with protease inhi-
bitors (Sigma). The protein concentration was deter-
mined using the Bradford assay (Bio-Rad). Lysis were
running in a 8-15% sodium dodecyl sulfate-polyacryla-
mide electrophoresis (SDS-PAGE) gel, transferred to
PVDF membranes (Millipore), and incubated with anti-
bodys against CDKN2A, cyclin D1, total retinoblas-
toma protein (tRb), phosphorylated Rb protein (pRb),
and actin (Cell Signal Technology) and visualized by
enhanced chemiluminescence plus (GE).
CDKN2A construct
Full-length human CDKN2A cDNA was amplified by
PCR from a human fetal brain cDNA library (Invitro-
gen) by using primers contained restriction enzyme
cleavage sites (EcoRIa n dBamH I), and cloned into
pcDNA3.1 vector (Invitrogen).
Small interfering RNA (siRNA) knockdown of CDKN2A
Transient silencing of the CDKN2A gene was achieved
using a pool of four siRNA duplexes (ONTARGETplus
SMARTpool, Dharmacon). The target sequences were as
follows: 5’-GATCATCAGTCACCGAAGG-3’,5 ’-AAA-
CACCGCTTCTGCCTTT-3’,5 ’- TAACGTAGATA-
TATGCCTT-3’,a n d5 ’-CAGAACCAAAGCTCAAATA-3’.
A mixture of four nontargeting siRNA duplexes was used
as a negative control (ON-TARGETplus Nontargetingv-
Pool, Dharmacon). Transfections of H4 and HS-683 cells
were performed using the Lipofectamine Plus transfection
reagent (Invitrogen) according to the manufacturer’s
instructions. The efficiency of CDKN2A knockdown was
detected by western blot 48 h after transfection.
Colony formation assay and growth curves
All glioma cells were transfected using Lipofectamin
Plus (Invitrogen) in accordance with the procedure
recommended by the manufacturer. Forty-eight hours
after tansfection, the cells were replated in 10 cm
2 plates
and maintained in selection medium containing 800 μg/
ml of G418 (GIBCO). Cultures were replated in the den-
sities of 1 × 10
3,5×1 0
2,o r2 . 5×1 0
2 on 10 cm
2 plates
in triplicates and maintained for 2 weeks. The neoresis-
tant colonies were fixed with methanol, stained with
Giemsa, and counted. The number of colonies on the
control dishes (transfected with pcDNA3.1 vector) was
used as the 100% in this assay.
The cells were transfected with pcDNA3.1 or
CDKN2A using Lipofectamin Plus. A mixed clones cells
were obtained after G418 (800 μg/ml) selection for 1
week. Growth curves were generated by plating 10
4 cells
in the DMEM medium for 24, 48 72 and 96 hours in
quadruples. The cells were harvested with trypsin and
counted at intervals.
Statistical analyses
Levels of CDKN2A are expressed as arithmetic means ±
95% confidence interval, statistical analysis was
Table 1 Summary of the pathological classification of glioma in index patients
Glioma classification WHO grade Male/Female N Age(years)
Pilocytic Astrocytoma(PA) I 3/1 4 27.1 ± 10.3
Astrocytoma(A) II 11/5 16 47.2 ± 6.9
Oligodendroglioma(O) II 3/3 6 54.8 ± 9.2
Low-Grade glioma 17/9 26 48.3 ± 9.1
Anaplastic Astrocytoma(AA) III 6/3 9 44.2 ± 10.7
Anaplastic Oligodendroglioma(AO) III 4/1 5 47.9 ± 5.4
Glioblastoma Multiforme(GBM) IV 16/5 21 55.3 ± 9.5
High-Grade glioma 26/9 35 52.2 ± 9.8
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results are expressed as mean ± SD. Values, statistical
analysis for the multiplicity was conducted using
ANOVA or Student’s t-test, where appropriate. The
results were considered to be statistically significant
when P values were < 0.05.
Results
Expression levels of CDKN2A in patients with malignant
gliomas and glioma cell lines
All of tumors were categorized based on the histopatho-
logic diagnosis. Tumor samples were reevaluated by a
neuropathologist to confirm the diagnosis and were
graded using the World Health Organization criteria.
Twenty-six tumors were classified as Low- Grade glioma
(Grade I and II), and thirty-five tumors were graded
High-Grade glioma (Grade III and IV). The stage of pri-
mary tumors as well as further patient characteristics
are shown in Table 1.
CDKN2A is an important positive regulator of the
cyclin-Rb signaling pathway involved in carcinogenesis
of glioma. To confirm the role of CDKN2A in gliomas,
we detected the levels of CDKN2A expression in 61
glioma tissues by immunohistochemstry (IHC) (Figure
1 A ,C )a n dw e s t e r nb l o t( F i g u r e1 B ) .O u rr e s u l t ss h o w
that the expression levels of CDKN2A in high-grade
glioma tissues were significant lower than that in low-
grade glioma tissues. Decreased CDKN2A in high-grade
Figure 1 The expression level of CDKN2A was associated with grade of gliomas. Immunohistochemistry of CDKN2A in low-grade glioma
(A), and high-grade glioma(B). Magnification, × 200. Immunohistochemistry statistical analysis results were shown. low-grade gliomas v.s high-
grade gliomas, p < 0.01 (B). Expression of CDKN2A was detected by western blot in low-grade glioma tissues and hig-grade glioma tissues. 1-8:
tissues from difference patients. (C). Expression of CDKN2A protein in glioma cell lines (D). Note that H4 and HS-683 are low-grade glioma cell
lines and the others were high-grade glioma cell lines. Actin as loading control.
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malignant glioma carcinogenesis. We also detected the
expression of CDKN2A in high (T98G, U251-MG, U87-
MG, A172, SW1736, U118-MG and U138-MG) and low
grade glioma cells (H4 and HS-683). The result shows
that the high grade glioma cells have a lower levels of
CDKN2A than that of low-grade glioma cells, which in
consistent with glioma tissues from patients (Figure 1E).
Reconstitution CDKN2A suppresses colony-forming ability
and growth rate of human malignant gliomas cells
The molecular function of CDKN2A in tumor cells is a
subject of considerable investigation, and it is still not
clear. To investigate whether anti-tumor effect of
CDKN2A are affected by exogenous CDKN2A, various
glioma cells were transfected with CDKN2A. As shown
in Figure 2, CDKN2A potently inhibited colony-forming
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Figure 2 Effect of CDKN2A on colony-forming ability of human glioma cells. CDKN2A suppresses colony-forming ability of human glioma
cells. All assays performed in triplicate. The results were present by mean ± SD. * P < 0.05, **P < 0.01 (Student’s t-test) in all cases. All
experiments were performed in triplicate.
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fection of CDKN2A into glioma cells resulted in a
reduction in the rate of cell growth (Figure 3). More-
over, siRNA knockdown was performed in some low-
grade glioma cell lines (H4 and HS-683). When the
expression of CDKN2A interfered effectively, the cell
growth accelerates. Our results indicated that suppres-
sing the expression of CDKN2A was able to promote
the low grade gliomas to high grade gliomas (Figure 4B
and 4C).
Antitumour effect of CDKN2A is Cyclin D1-dependent
To determine the role of the CDKN2A-Cyclin-Rb path-
way in glioma, Western blot analysis was used to detect
changes in expression of cell cycle regulatory proteins.
Overexpression of CDKN2A had same effects on the
CDKN2A-Cyclin-Rb pathway proteins in various cell
lines (Figure 4). After overexpression of CDKN2A in
glioblastoma cell lines T98G, U87-MG and SW1783
MG, the expression of cyclin D1 was decreased. The
phosphorylation of Rb protein (pRb) was also decreased
in all cell lines, but the level of total Rb was not
markedly reduced as phosphorylation of pRb. In con-
trast, we observed elevated levels of cyclin D1 and pRb
when CDKN2A was knockdown. However, flavopiridola,
an available cyclin D1 inhibitor [10,11] reserved the
accelerated cell growth and the increased phosphoryla-
tion of pBb induced by CDKN2A knockdown in low-
grade glioma cells (Figure 4B, C and Figure 5B). More-
over, a higher expression of Cylin D1 was observed in
high-grade tumor tissues than that of low-grade tumor
tissues (Figure 5C). The expression of Cylin D1 reversely
correlates with CDKN2A expression in patients glioma
tissues. These results suggest that antitumour effect of
CDKN2A is cyclin D1-dependent.
Discussion
Genome-wide association study identifies that CDKN2A
was a susceptibility loci for glioma [12]. It was reported
that CDKN2A be mutated and deleted in various
human tumors, including more than 70% of human
glioma cell lines and glioblastoma [13-16]. In this study,
we identify that expression of CDKN2A was associated
with grade of glioma in 61 patients with malignant
glioma and glioma cells. Lower level of CDKN2A was
correlation with a worse prognosis. Moreover, overex-
pression of CDKN2A suppresses colony-forming ability
and cell growth of various giloma cell lines. It indicated
that the level of CDKN2A expression may present the
feedback mechanisms of the cell cycle in the malignant
cell populations. Subsequently, we investigated the effect
of CDKN2A on cell cycle by overexpression of
CDKN2A in vitro. Overexpression of CDKN2A sup-
presses colony-forming ability and growth rate of
human malignant glioma cells. However, knockdown of
CDKN2A promotes the low grade gliomas to high grade
gliomas.
There are three major pathways affected in a high per-
centage of glioblastomas: receptor tyrosine kinase signal-
ing, TP53 signaling and the pRB tumor suppressor
pathway [6,17]. The receptor tyrosine kinase (RTK) sig-
naling pathway was involved in the translation of growth
factor signals into increased proliferation and survival.
The altered genes in the RTK pathway include EGFR,
PTEN, PIK3CA, RAS and TP53 signaling was important
in apoptosis, cellular senescence and cell cycle arrest in
response to DNA damage. Two TP53 inhibitors, MDM2
and MDM4, mediated the ubiquitinylation and degrada-
tion of TP53. Also, the CDKN2A locus was frequently
deleted or inactivated in glioblastomas and was involved
in both the TP53 pathway and pRB pathway. The pRB
is a major protein involved in cell cycle progression
from G1 to S phase. CDK4, CDK6 and the hypopho-
sphorylated state pRB bind to the transcription factor
E2F, thereby preventing cell cycle progression. Conver-
sely, CDKN2A/CDKN2AINK4A, CDKN2B and
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Figure 3 Effect of CDKN2A on cell growth. CDKN2A reduced the
growth of U87-MG (A) and SW1738 (B) glioma cell lines. U87-MG
and SW1738 were transfected with pCDNA 3.1 vector and CDKN2A
respectively. A mixed clones cells were obtained after G418 (800
μg/ml) selection for 1 week. Growth curve experiment was
performed. The results were present by mean ± SD. * P < 0.05, **P
< 0.01 (Student’s t-test) in all cases. All experiments were performed
in triplicate.
Liu et al. Journal of Experimental & Clinical Cancer Research 2011, 30:76
http://www.jeccr.com/content/30/1/76
Page 5 of 7Figure 4 Konckdown of CDKN2A promotes the low grade gliomas to high grade gliomas. Western blot analysis revealed a markedly
decreased expression of CDKN2A after tranfecting a pool of four siRNA duplexes for CDKN2A in HS-683 and H4 cell lines(A). Knockdown of
CDKN2A accelerates the growth of HS-683 (B) and H4 (C) glioma cell lines. However, flavopiridola, a cyclin D1 inhibitor, can reverse the
accelerated cell growth both of HS-683 and H4 cell lines.
Figure 5 CDKN2A negatively regulated pRb and down-regulated level of cell cycle regulatory protein cyclin D1. Western blot analysis
revealed a markedly lower phosphorylation of pRb and expression of cyclin D1 in T98G, U87-MG and SW1783 glioma cell lines transfected with
CDKN2A (A). However, knockdown of CDKN2A increased the phosphorylation of pRb and cyclin D1 in H4 glioma cell line. Moreover, a cyclin D1
inhibitor flavopiridol blocked the elevated phosphorylation of pRb and the expression of cyclin D1 induced by CDKN2A knockdown (B).
Increased cyclin D1 also detected in high-grade gliomas tissues comparing low-grade gliomas tissues (C). Three independent experiments were
preformed. A representative result was shown. pRb, phosphorylated Rb; tRb, total Rb. Actin as a loading control.
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Page 6 of 7CDKN2C, inhibit the different CDKs and are frequently
inactivated in GBM. The CDKN2A acts as a cyclin-
dependent kinase inbibitor, inbibiting the binding of the
CDK4 protein to cylclin D1 and thus preventing phos-
phorylation of the Rb protein and arresting the cell
cycle in the G1phase [18,19]. Cyclin D1 overexpression,
CDKN2A loss, and pRb inactivation play a key role in
glioma tumorigenesis [20-22]. The results indicated that
overexpression CDKN2A has the potential to be devel-
oped into a future treatment for glioma patients.
Conclusions
Our study suggests that CDKN2A as a malignant glio-
mas suppressor gene, appears to be useful for predicting
behaviour of high-grade malignant gliomas. CDKN2A-
Cyclin-Rb pathway plays a key role on malignant glio-
mas formation and that therapeutic targeting of this
pathway may be useful in malignant gliomas treatment.
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